150 related articles for article (PubMed ID: 16680835)
1. Markers of bone metabolism in prostate cancer.
Smith MR
Cancer Treat Rev; 2006; 32 Suppl 1():23-6. PubMed ID: 16680835
[TBL] [Abstract][Full Text] [Related]
2. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.
Saad F; Eastham JA; Smith MR
Urol Oncol; 2012; 30(4):369-78. PubMed ID: 21163673
[TBL] [Abstract][Full Text] [Related]
3. Bone metabolic markers in bone metastases.
Koizumi M; Yamada Y; Takiguchi T; Nomura E; Furukawa M; Kitahara T; Yamashita T; Maeda H; Takahashi S; Aiba K
J Cancer Res Clin Oncol; 1995; 121(9-10):542-8. PubMed ID: 7559734
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
5. [Biphosphonates in the treatment of bone metastasis of prostatic cancer].
Paule B; Cicco A
Prog Urol; 2001 Dec; 11(6):1205-12. PubMed ID: 11859653
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications.
Nelson EC; Evans CP; Pan CX; Lara PN
World J Urol; 2007 Aug; 25(4):393-9. PubMed ID: 17562051
[TBL] [Abstract][Full Text] [Related]
7. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
Smith MR; Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F
Urology; 2007 Aug; 70(2):315-9. PubMed ID: 17826496
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.
Ricci E; Mattei E; Dumontet C; Eaton CL; Hamdy F; van der Pluije G; Cecchini M; Thalmann G; Clezardin P; Colombel M
Prostate; 2013 Dec; 73(16):1738-46. PubMed ID: 24115186
[TBL] [Abstract][Full Text] [Related]
9. Bone metabolism and new targets for intervention.
Akduman B; Crawford ED
Curr Urol Rep; 2007 May; 8(3):233-8. PubMed ID: 17459273
[TBL] [Abstract][Full Text] [Related]
10. The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
Özdemir BC; Hensel J; Secondini C; Wetterwald A; Schwaninger R; Fleischmann A; Raffelsberger W; Poch O; Delorenzi M; Temanni R; Mills IG; van der Pluijm G; Thalmann GN; Cecchini MG
PLoS One; 2014; 9(12):e114530. PubMed ID: 25485970
[TBL] [Abstract][Full Text] [Related]
11. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone.
Keller ET; Zhang J; Cooper CR; Smith PC; McCauley LK; Pienta KJ; Taichman RS
Cancer Metastasis Rev; 2001; 20(3-4):333-49. PubMed ID: 12085970
[TBL] [Abstract][Full Text] [Related]
12. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
13. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
14. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
Keller ET; Brown J
J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
[TBL] [Abstract][Full Text] [Related]
16. Investigations on bone metabolism of urological tumors forming metastases.
Bichler KH; Petri E; Hub A; Kleinknecht S; Heidenreich A
Urol Int; 1996; 56(2):61-8. PubMed ID: 8659012
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Michaelson MD; Kaufman DS; Kantoff P; Oh WK; Smith MR
Cancer; 2006 Aug; 107(3):530-5. PubMed ID: 16804927
[TBL] [Abstract][Full Text] [Related]
18. Role of Wnts in prostate cancer bone metastases.
Hall CL; Kang S; MacDougald OA; Keller ET
J Cell Biochem; 2006 Mar; 97(4):661-72. PubMed ID: 16447163
[TBL] [Abstract][Full Text] [Related]
19. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]